T
Teresa Bernal del Castillo
Researcher at University of Salamanca
Publications - 29
Citations - 1202
Teresa Bernal del Castillo is an academic researcher from University of Salamanca. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 7, co-authored 14 publications receiving 851 citations. Previous affiliations of Teresa Bernal del Castillo include International Sleep Products Association.
Papers
More filters
Journal ArticleDOI
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret,John F. Seymour,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Giovanni Martinelli,Jose F Falantes,Richard Noppeney,Richard Stone,Mark D. Minden,Heidi McIntyre,S. Songer,Lela M. Lucy,C.L. Beach,Hartmut Döhner +23 more
TL;DR: Univariate analysis showed favorable trends for azacitidine compared with CCR across all subgroups defined by baseline demographic and disease features, and adverse events were consistent with the well-established safety profile of azacItidine.
Journal ArticleDOI
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Hartmut Döhner,Anna Dolnik,Lin Tang,John F. Seymour,Mark D. Minden,Richard Stone,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Valeria Santini,Paresh Vyas,C.L. Beach,Kyle J. MacBeth,Barry S. Skikne,S. Songer,Nora Tu,Lars Bullinger,Lars Bullinger,Hervé Dombret +17 more
TL;DR: Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics, particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes.
Journal ArticleDOI
Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort
Jordi Esteve,Rik Schots,Teresa Bernal del Castillo,Je-Hwan Lee,Eunice S. Wang,Shira Dinner,Mark D. Minden,Olga Salamero,Jorge Sierra,Goichi Yoshimoto,Kamel Laribi,Janusz Hałka,Pau Montesinos,Shufang Liu,Elizabeth Shima Rich,Erkut Bahceci +15 more
TL;DR: This abstract presents data from the Safety Cohort which evaluated only gilteritinib plus AZA, a highly selective, potent FLT3/AXL inhibitor, which showed antileukemic activity with favorable tolerability in a phase 1/2 trial of patients with newly diagnosedFLT3mut+ relapsed/refractory AML.
Journal ArticleDOI
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
John F. Seymour,John F. Seymour,Hartmut Döhner,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Jose F Falantes,Richard Stone,Mark D. Minden,Jerry Weaver,S. Songer,C.L. Beach,Hervé Dombret +21 more
TL;DR: Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65–74 years and those with intermediate-risk cytogenetics.
Journal ArticleDOI
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Lisa Pleyer,Michael Leisch,Alexandra Kourakli,Eric Padron,Jaroslaw P. Maciejewski,Blanca Xicoy Cirici,Jennifer Kaivers,Johanna Ungerstedt,Sonja Heibl,Peristera Patiou,Anthony M. Hunter,Elvira Mora,Klaus Geissler,Maria Dimou,Maria-José Jimenez Lorenzo,Thomas Melchardt,Alexander Egle,Athina-Nora Viniou,Bhumika J. Patel,Montserrat Arnan,Peter Valent,Christoforos Roubakis,Teresa Bernal del Castillo,Athanasios Galanopoulos,Marisa Calabuig Muñoz,Nicolas Bonadies,Antonio Almeida,Jaroslav Cermak,Andres Jerez,Maria Julia Montoro,Albert Cortés,Alejandro Avendaño Pita,B. Andrade,Eva Hellstroem-Lindberg,Ulrich Germing,Mikkael A. Sekeres,Alan F. List,Argiris Symeonidis,Guillermo Sanz,Guillermo Sanz,Julian Larcher-Senn,Richard Greil +41 more
TL;DR: In this article, the authors investigated whether hypomethylating agents provided a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments.